Tomás Pascual

5.4k total citations · 1 hit paper
133 papers, 1.6k citations indexed

About

Tomás Pascual is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Tomás Pascual has authored 133 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Oncology, 83 papers in Pulmonary and Respiratory Medicine and 62 papers in Cancer Research. Recurrent topics in Tomás Pascual's work include Advanced Breast Cancer Therapies (70 papers), HER2/EGFR in Cancer Research (62 papers) and Breast Cancer Treatment Studies (54 papers). Tomás Pascual is often cited by papers focused on Advanced Breast Cancer Therapies (70 papers), HER2/EGFR in Cancer Research (62 papers) and Breast Cancer Treatment Studies (54 papers). Tomás Pascual collaborates with scholars based in Spain, United States and Italy. Tomás Pascual's co-authors include Aleix Prat, Patricia Galván, Fara Brasó‐Maristany, Montserrat Muñoz-Mateu, Laia Paré, María Vidal, Francesco Schettini, Bárbara Adamo, Núria Chic and Eva Ciruelos and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Tomás Pascual

117 papers receiving 1.6k citations

Hit Papers

Frequency and spectrum of PIK3CA somatic mutations in bre... 2020 2026 2022 2024 2020 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Frequency and spectrum of PIK3CA somatic mutations in breast cancer
    2020 227 citations Olga Martínez‐Sáez, Núria Chic et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tomás Pascual Spain 19 1.0k 585 488 382 230 133 1.6k
Laura Pizzuti Italy 23 906 0.9× 333 0.6× 410 0.8× 454 1.2× 206 0.9× 96 1.7k
Rohan Garje United States 17 1.1k 1.1× 556 1.0× 249 0.5× 429 1.1× 422 1.8× 79 1.8k
Nicola Battelli Italy 23 1.0k 1.0× 814 1.4× 553 1.1× 512 1.3× 274 1.2× 91 1.9k
Tom Wei‐Wu Chen Taiwan 19 1.4k 1.4× 745 1.3× 202 0.4× 394 1.0× 387 1.7× 91 2.0k
Antonella Spila Italy 25 744 0.7× 319 0.5× 308 0.6× 500 1.3× 291 1.3× 64 1.6k
Alain Gelibter Italy 22 974 1.0× 574 1.0× 333 0.7× 332 0.9× 127 0.6× 100 1.4k
K. Syrigos Greece 23 1.1k 1.1× 638 1.1× 288 0.6× 388 1.0× 138 0.6× 73 1.9k
Florian Hohla Austria 23 1.0k 1.0× 411 0.7× 330 0.7× 349 0.9× 60 0.3× 41 1.8k
Consuelo Buttigliero Italy 23 692 0.7× 1.0k 1.8× 397 0.8× 411 1.1× 70 0.3× 91 1.7k
Dale R. Shepard United States 17 478 0.5× 470 0.8× 258 0.5× 419 1.1× 107 0.5× 75 1.2k

Countries citing papers authored by Tomás Pascual

Since Specialization
Citations

This map shows the geographic impact of Tomás Pascual's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomás Pascual with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomás Pascual more than expected).

Fields of papers citing papers by Tomás Pascual

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomás Pascual. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomás Pascual. The network helps show where Tomás Pascual may publish in the future.

Co-authorship network of co-authors of Tomás Pascual

This figure shows the co-authorship network connecting the top 25 collaborators of Tomás Pascual. A scholar is included among the top collaborators of Tomás Pascual based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomás Pascual. Tomás Pascual is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oliveira, Mafalda, Eva Ciruelos, Guillermo Villacampa, et al.. (2025). Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial. Clinical Cancer Research. 32(3). 468–478.
2.
Sanfeliu, Esther, Elia Seguí, Raquel Gómez Bravo, et al.. (2024). Abstract PO2-01-13: Clinico-Pathological and Molecular Characterization of Early Hormone Receptor-Positive Breast Cancer in Young Women. Cancer Research. 84(9_Supplement). PO2–1. 1 indexed citations
3.
Villacampa, Guillermo, Tomás Pascual, Fara Brasó‐Maristany, et al.. (2024). Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B). ESMO Open. 9(3). 102388–102388. 7 indexed citations
4.
Ciruelos, Eva, Tomás Pascual, Guillermo Villacampa, et al.. (2024). Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer.. Journal of Clinical Oncology. 42(16_suppl). 1008–1008. 4 indexed citations
5.
Pernas, Sònia, Esther Sanfeliu, Guillermo Villacampa, et al.. (2024). Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy. npj Breast Cancer. 10(1). 101–101.
6.
Tolaney, Sara M., Nadine Tung, Antonio C. Wolff, et al.. (2024). HER2DX genomic test in early-stage HER2-positive breast cancer. ESMO Open. 9(12). 103987–103987. 8 indexed citations
7.
Schmiester, Leonard, Fara Brasó‐Maristany, Blanca González‐Farré, et al.. (2024). Computational Model Predicts Patient Outcomes in Luminal B Breast Cancer Treated with Endocrine Therapy and CDK4/6 Inhibition. Clinical Cancer Research. 30(17). 3779–3787. 1 indexed citations
8.
Waks, Adrienne G., Olga Martínez‐Sáez, Paolo Tarantino, et al.. (2024). Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance. Nature Reviews Clinical Oncology. 21(11). 818–832. 7 indexed citations
9.
Villacampa, Guillermo, Vı́ctor Navarro, Alexios Matikas, et al.. (2024). Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer. JAMA Oncology. 10(10). 1331–1331. 29 indexed citations
10.
Schettini, Francesco, Tomás Pascual, Fara Brasó‐Maristany, et al.. (2023). 55P Clinicopathological and molecular changes induced by neoadjuvant therapy (NAT) in hormone receptor-positive (HR+)/HER2-low vs HER2 0 breast cancer (BC). ESMO Open. 8(1). 101279–101279. 1 indexed citations
11.
Pascual, Tomás, Juan Miguel Cejalvo, Mafalda Oliveira, et al.. (2023). 387MO First results of the SOLTI-1903 HOPE's patient-centric molecular screening program in advanced breast cancer. Annals of Oncology. 34. S341–S342. 1 indexed citations
12.
Pascual, Tomás, Blanca González‐Farré, Fara Brasó‐Maristany, et al.. (2023). 2239P Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types. Annals of Oncology. 34. S1153–S1154. 1 indexed citations
13.
Fernández-Martínez, Aranzazu, Tomás Pascual, Baljit Singh, et al.. (2023). Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer. JAMA Oncology. 9(4). 490–490. 36 indexed citations
14.
Villacampa, Guillermo, Claudette Falato, Laia Paré, et al.. (2022). Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial. European Journal of Cancer. 174. 232–242. 4 indexed citations
15.
Pascual, Tomás, Mafalda Oliveira, Patricia Villagrasa, et al.. (2021). Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. npj Breast Cancer. 7(1). 145–145. 8 indexed citations
16.
Prat, Aleix, Yi‐Hsuan Tsai, Tomás Pascual, et al.. (2020). A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer. Clinical Cancer Research. 26(23). 6141–6148. 5 indexed citations
17.
Pascual, Tomás, Juan Miguel Cejalvo, Mafalda Oliveira, et al.. (2020). SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. Future Oncology. 16(24). 1801–1813. 9 indexed citations
18.
Adamo, Bárbara, Lorena Moreno, Lydia Gaba, et al.. (2019). Multi-gene panel testing at the hereditary breast and ovarian cancer (HBOC) unit of the Hospital Clinic of Barcelona. Annals of Oncology. 30. iii42–iii43.
19.
Griguolo, Gaia, Tomás Pascual, Maria Vittoria Dieci, Valentina Guarneri, & Aleix Prat. (2019). Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. Journal for ImmunoTherapy of Cancer. 7(1). 90–90. 76 indexed citations
20.
Prat, Aleix, Alejandro Navarro, Laia Paré, et al.. (2017). Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. Cancer Research. 77(13). 3540–3550. 277 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laura Pizzuti Breakdown of academic impact, for papers by Rohan Garje Breakdown of academic impact, for papers by Nicola Battelli Breakdown of academic impact, for papers by Tom Wei‐Wu Chen Breakdown of academic impact, for papers by Antonella Spila Breakdown of academic impact, for papers by Alain Gelibter Breakdown of academic impact, for papers by K. Syrigos Breakdown of academic impact, for papers by Florian Hohla Breakdown of academic impact, for papers by Consuelo Buttigliero Breakdown of academic impact, for papers by Dale R. Shepard
Rankless by CCL
2026